Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Muscular Dystrophy

Lucid Diligence Brief - BioPharma

Servier Completes Edgewise Muscular Dystrophy Acquisition | Lucid Diligence Brief

Servier Completes the Edgewise Muscular Dystrophy Acquisition and Adds…

by Eugenia Tsempera

Lucid Diligence Brief - BioPharma

Servier Edgewise Sevasemten Deal | Lucid Diligence Brief

Servier’s Edgewise acquisition puts sevasemten’s Becker muscular dystrophy data…

by Marione Briones

Rare Disease news

Rare Diseases Weekly News - July 24th 2025

🧬 This Week in Rare Diseases: Breakthrough Therapies, AI Innovations,…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
LucidScope AI Audit Analyses
Public Health News
Monthly Strategic Roundups
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Excalipoint Therapeutics and DP Technology Partnership | Lucid Diligence Brief
Nucleai-University of Glasgow Partnership Expands Spatial AI Platform | Lucid Diligence Brief
Public Health Strategic Roundup | June 11–July 15, 2026
Immunology Strategic Roundup | June 9–July 14, 2026
AI perception of Lipid-Lowering Therapies | LucidScope AI Visibility Audit

Tags

AB-1002 Ancora Heart AT7687 Atsena Therapeutics Biosolution Bomedemstat Bulumtatug Fuvedotin Cantargia capital markets CorFlow Therapeutics CRL Cure Rare Disease dCK Deep Research Max Desmoid Tumors EnsoData FDA Fast Track designation finalspark G-CROWN Health misinformation High-Risk Smoldering Multiple Myeloma Hinge Health IHH Healthcare immune checkpoint inhibitors iopofosine I-131 JR-446 KRAS vaccine Kyverna Therapeutics lonafarnib Non-ST-Elevation Myocardial Infarction Oruka Therapeutics OTXL Ozekibart Preventive genomics sex differences in MI shared decision-making SION-719 SleepSpace SNG-101 SQ Innovation synthetic vaccine UB-VV111 Vaccination WHO South-East Asia WIN378

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Excalipoint Therapeutics and DP Technology Partnership | Lucid Diligence Brief
Nucleai-University of Glasgow Partnership Expands Spatial AI Platform | Lucid Diligence Brief
Public Health Strategic Roundup | June 11–July 15, 2026
Immunology Strategic Roundup | June 9–July 14, 2026
AI perception of Lipid-Lowering Therapies | LucidScope AI Visibility Audit

TAGS

AB-1002 Ancora Heart AT7687 Atsena Therapeutics Biosolution Bomedemstat Bulumtatug Fuvedotin Cantargia capital markets CorFlow Therapeutics CRL Cure Rare Disease dCK Deep Research Max Desmoid Tumors EnsoData FDA Fast Track designation finalspark G-CROWN Health misinformation High-Risk Smoldering Multiple Myeloma Hinge Health IHH Healthcare immune checkpoint inhibitors iopofosine I-131 JR-446 KRAS vaccine Kyverna Therapeutics lonafarnib Non-ST-Elevation Myocardial Infarction Oruka Therapeutics OTXL Ozekibart Preventive genomics sex differences in MI shared decision-making SION-719 SleepSpace SNG-101 SQ Innovation synthetic vaccine UB-VV111 Vaccination WHO South-East Asia WIN378

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy